Potential for infusion correction of COVID-19-associated endotheliopathy
Authors:
- Ionas S. SimutisISIonas S. Simutis
- Viacheslav A. RatnikovVRViacheslav A. Ratnikov
- Alexey N. ScheglovASAlexey N. Scheglov
- Olga V. NikolaevaONOlga V. Nikolaeva
- Gennady A. BoyarinovGBGennady A. Boyarinov
- Alexander A. SapeginASAlexander A. Sapegin
- Larisa B. GaikovayaLGLarisa B. Gaikovaya
- Darya A. EvteevaDEDarya A. Evteeva
- Ksenia N. ZamyatinaKZKsenia N. Zamyatina
Open Access
- 17 August 2023
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 487-493
Abstract
Aim. To evaluate the relationship between the systemic inflammatory response and the severity of COVID-19-associated endotheliopathy and the effect of succinate-containing crystalloid solution (sodium meglumine succinate) on it in patients with severe COVID-19. Materials and methods. Clinical and laboratory parameters of 53 intensive care unit's patients with COVID-19 complicated by community-acquired bilateral multisegmental pneumonia were analyzed. Intensive therapy complex of 27 patients (study group) included daily infusion of 1.5% solution of sodium meglumine succinate (Reamberin) in the daily dose of 10 ml/kg for at least 11 days (or during the whole stay in the unit). A similar volume of Ringer's solution was present in the control group of 26 patients. The levels of endotheliocytosis, homocysteine, and systemic inflammatory response were determined at all stages of the study. Results. The evaluation of endotheliopathy degree in the meglumine succinate group showed a significant reduction of initially elevated levels of endotheliemia and homocysteinemia at all study stages. The pattern of changes in the study group was highly correlated (r=0.900.96) with the dynamics of systemic inflammatory response parameters-fibrinogenemia, C-reactive protein and interleukin-6 levels. As normalization of the immune imbalance, we regarded the termination of lymphopenia in the Reamberin group. Conclusion. Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.Keywords
This publication has 17 references indexed in Scilit:
- Thromboinflammation and the hypercoagulability of COVID‐19Journal of Thrombosis and Haemostasis, 2022
- Circulating endothelial progenitors are increased in COVID‐19 patients and correlate with SARS‐CoV‐2 RNA in severe casesJournal of Thrombosis and Haemostasis, 2020
- Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?Pharmaceuticals, 2020
- Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wallBiochimie, 2020
- Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysisJournal of Intensive Care, 2020
- Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stageJournal of Translational Medicine, 2020
- SARS-CoV-2 and viral sepsis: observations and hypothesesThe Lancet, 2020
- The trinity of COVID-19: immunity, inflammation and interventionNature Reviews Immunology, 2020
- C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 earlyJournal of Medical Virology, 2020
- Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patientsAging, 2020